These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21519244)

  • 1. Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma.
    Sweetenham JW
    Curr Opin Hematol; 2011 Jul; 18(4):288-92. PubMed ID: 21519244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas--a review article.
    Jabłońska J; Jesionek-Kupnicka D
    Pol J Pathol; 2008; 59(3):121-7. PubMed ID: 19097355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.
    Li D; Xie P; Mi C
    Pathol Res Pract; 2010 Sep; 206(9):611-5. PubMed ID: 20627604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
    Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
    Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.
    Saad AA; Awed NM; Abdel-Hafeez ZM; Kamal GM; Elsallaly HM; Alloub AI
    Saudi Med J; 2010 Feb; 31(2):135-41. PubMed ID: 20174727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
    Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
    APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
    Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
    J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
    Tagawa H
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diffuse Large B cell Lymphoma -  Modern Dia-gnostics and Molecularly Targeted Treatment].
    Pytlík R; Trněný M
    Klin Onkol; 2015; 28 Suppl 3():3S64-72. PubMed ID: 26489504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma.
    Dierlamm J; Murga Penas EM; Bentink S; Wessendorf S; Berger H; Hummel M; Klapper W; Lenze D; Rosenwald A; Haralambieva E; Ott G; Cogliatti SB; Möller P; Schwaenen C; Stein H; Löffler M; Spang R; Trümper L; Siebert R;
    Haematologica; 2008 May; 93(5):688-96. PubMed ID: 18367485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the molecular diagnosis of diffuse large B-cell lymphoma.
    Fu K; Iqbal J; Chan WC
    Expert Rev Mol Diagn; 2005 May; 5(3):397-408. PubMed ID: 15934816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.
    Gormley RP; Madan R; Dulau AE; Xu D; Tamas EF; Bhattacharyya PK; LeValley A; Xue X; Kumar P; Sparano J; Ramesh KH; Pulijaal V; Cannizzaro L; Walsh D; Ioachim HL; Ratech H
    Am J Clin Pathol; 2005 Nov; 124(5):790-8. PubMed ID: 16203284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.
    Hallermann C; Niermann C; Fischer RJ; Schulze HJ
    J Am Acad Dermatol; 2007 Apr; 56(4):588-97. PubMed ID: 17289214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
    Zinzani PL; Broccoli A; Stefoni V; Musuraca G; Abruzzese E; De Renzo A; Cantonetti M; Bacci F; Baccarani M; Pileri SA
    Cancer; 2010 Dec; 116(24):5667-75. PubMed ID: 20737566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas.
    Miles RR; Mankey CC; Seiler CE; Smith LB; Teruya-Feldstein J; Hsi ED; Elenitoba-Johnson KS; Lim MS
    Hum Pathol; 2009 Dec; 40(12):1731-7. PubMed ID: 19716163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy.
    de Jong D; Balagué Ponz O
    J Pathol; 2011 Jan; 223(2):274-82. PubMed ID: 21125680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway.
    Ray DM; Morse KM; Hilchey SP; Garcia TM; Felgar RE; Maggirwar SB; Phipps RP; Bernstein SH
    Exp Hematol; 2006 Sep; 34(9):1202-11. PubMed ID: 16939813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.